2-methyl 1-(2-methyl-2-propanyl) (2S,3R,4S)-3,4-dihydroxy-1,2-pyrrolidinedicarboxylate | 204398-85-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-methyl 1-(2-methyl-2-propanyl) (2S,3R,4S)-3,4-dihydroxy-1,2-pyrrolidinedicarboxylate
• 英文别名: Boc-Dyp-OMe；(2S,3R,4S)-1-tert-butyl 2-methyl 3,4-dihydroxypyrrolidine-1,2-dicarboxylate；1-tert-butyl 2-methyl (2S,3R,4S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate；1-O-tert-butyl 2-O-methyl (2S,3R,4S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate
• CAS: 204398-85-6
• 化学式: C₁₁H₁₉NO₆
• 分子量: 261.275
• InChiKey: CJRMRCKYHVRIFE-FXQIFTODSA-N

物化性质

• 沸点：
  359.7±42.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  96.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-methyl 1-(2-methyl-2-propanyl) (2S,3R,4S)-3,4-dihydroxy-1,2-pyrrolidinedicarboxylate 在 三苯基膦 作用下， 以 四氯化碳 为溶剂， 反应 12.0h， 以74.5%的产率得到3,4-(3S,4R)-dichloropyrrolidine-1,2-(2S)-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  参考文献：
  名称：

  Synthetic studies toward astins A, B and C. Efficient syntheses of cis-3,4-dihydroxyprolines and (−)-(3S,4R)-dichloroproline esters

  摘要：

  Efficient syntheses of the esters of cis-3,4-dihydroxyprolines and the first synthesis of the ester of the rare amino acid (-)-(3S,4R)-dichloroproline from trans-4-hydroxy-L-proline are presented. The synthetic route provides easy access to several substituted prolines and cis-hydroxylated proline esters. Various types of biological activities have been associated with these substituted prolines. The role of (-)-(3S,4R)-dichloroproline in astins A, B and C is under investigation. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(97)00617-4
• 作为产物：
  描述：

  (4R)-N-Boc-4-iodo-L-proline methyl ester 在 四氧化锇 、 NMO 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 水 、 丙酮 、 甲苯 、 叔丁醇 为溶剂， 反应 16.0h， 生成 2-methyl 1-(2-methyl-2-propanyl) (2S,3R,4S)-3,4-dihydroxy-1,2-pyrrolidinedicarboxylate
  参考文献：
  名称：

  阳极氧化合成核糖氮杂核苷：中间体的反应性控制，可高效利用药效基团。

  摘要：

  糖修饰的核苷类似物氮杂核苷具有多种生物学活性，而其有效的合成策略仍在开发中。本文报道了一种通过使用硝基烷烃-高氯酸锂介质通过位点特异性阳极CH活化来合成药学上相关的氮杂核苷，核糖氮杂核苷的β-端基异构体的新方法。从传统糖化学方法对电化学反应和武装/解除武装的概念进行的机理研究表明，2'取代基对脯氨醇衍生物的反应性具有重大影响，合适的羧酸添加剂可以控制中间体物种（亚胺）的反应性阳离子当量。最后，

  DOI：

  10.1002/chem.201804285

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• [EN] OXIM DERIVATIVES AS HSP90 INHIBITORS<br/>[FR] DÉRIVÉS D'OXIME EN TANT QU'INHIBITEURS DE HSP90
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009097578A1

  公开（公告）日：2009-08-06

  The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及具有式(I)结构的HSP90抑制化合物，其中变量如本文所定义。本发明还涉及包含此类化合物的药物组合物、套件和制造品；制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• Aza-benzofuranyl compounds and methods of use
  申请人：Savy Pierre Pascal

  公开号：US20080085886A1

  公开（公告）日：2008-04-10

  The invention relates to azabenzofuranyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗癌和/或抗炎活性的Formula I的氮杂苯并呋喃化合物，更具体地涉及抑制MEK激酶活性的氮杂苯并呋喃化合物。本发明提供了用于抑制异常细胞生长或治疗哺乳动物的增生性疾病或治疗炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Synthetic Marine Sponge Collagen by Late-Stage Dihydroxylation
  作者：Christoph Priem、Armin Geyer

  DOI：10.1021/acs.orglett.7b03525

  日期：2018.1.5

  Based on the observation that an increased substrate size is paralleled by an enhanced diastereoselectivity, a late-stage dihydroxylation protocol toward the 21mer CMP (collagen model peptide) Ac-(Pro-Hyp-Gly)(3)-Pro-Dyp-Gly-(Pro-Hyp-Gly)(3)-NH2 is presented. C3 and C4 hydroxylation have a converse effect on the triple-helical stability of collagen. Their combined influence on the melting temperature was studied by NMR spectroscopy.
• WO2008/24725
  申请人：——

  公开号：——

  公开（公告）日：——